Drug intelligence / Profile preview

IDP-003

Development stage: Preclinical
Lead developer: InduPro
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

IDP-003 is a preclinical-stage bispecific antibody developed by InduPro. It functions as a PD-1 agonist and is being investigated for its potential in autoimmune diseases. Sanofi has entered into a collaboration with InduPro for this program, which includes an equity investment and a right of first negotiation.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD2 (T-cell Surface Antigen CD2)

Beyond the preview

Go deeper on IDP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-003.

Explore the full profile